JCB logo
amgmicro.com
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 16 October 2006. doi:10.1083/jcb.1752rr4
The Rockefeller University Press, 0021-9525 $8.00
JCB, Volume 175, Number 2, 197-197
This Article
Right arrow Full Text (PDF, 969K)
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wells, W. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wells, W. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Research Roundup

Innate tumorigenesis


A pathway required for innate immunity is also required to keep tumorigenic cells alive, report Yuchen Chien, Michael White (University of Texas Southwestern, Dallas, TX), and colleagues.

The RalB GTPase heads one of three pathways downstream of Ras that help drive tumorigenesis (the others are headed by MAP kinase and PI3K). This tumorigenic proliferation often triggers apoptosis. Preventing the apoptosis downstream of RalB, according to the Texas group, is Sec5. (Sec5's partners in secretion are not necessary, however.)

Also required was TBK1, an atypical I{kappa}B kinase that was found to bind Sec5. It is better known as part of the innate immune response. Sure enough, viruses induced RalB activity and transcription downstream of TBK1.

Why the connection? Virus-infected cells may stave off death long enough so that they can produce interferons, and this anti-death pathway may have been coopted by cancers. Or the pathway may be used for completely different purposes in the different locations. Either way, says White, the tumorigenesis "makes the [cells] more dependent on a pathway normally not required for survival." Such conditional dependencies "might be ideal therapeutic targets." Formula

Reference:

Chien, Y., et al. 2006. Cell. 127:157–170.[CrossRef][Medline]



William A. Wells

wellsw{at}rockefeller.edu


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Full Text (PDF, 969K)
Right arrow Alert me when this article is cited
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wells, W. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wells, W. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?


  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents